Evaluation of Paclitaxel Eluting Stent vs Paclitaxel Eluting Balloon Treating Peripheral Artery Disease of the Femoral Artery

NCT ID: NCT01728441

Last Updated: 2014-05-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-10-31
• Study Completion Date: 2014-05-31

Brief Summary

Objective of the REAL PTX trial is to compare paclitaxel-eluting stents to paclitaxel-eluting balloons for treating symptomatic peripheral artery disease of the femoropopliteal artery.

Detailed Description

The REAL PTX trial has been designed as prospective, randomized, multi-center, post-market study investigating the effect of the paclitaxel-eluting stent Zilver® PTX® (DES)in comparison to the use of a paclitaxel eluting balloon (DEB)in treating symptomatic peripheral artery disease of the femoropopliteal artery.

Up to 150 patients will be enrolled in Germany and Belgium. Enrollment is expected to be completed within approximately six months of initiating the study.

One group (DES or DEB) will be considered to yield significantly better results of the primary patency rate than the other group at 12 months follow up.

Conditions

Peripheral Artery Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Paclitaxel Eluting Stent

Patients randomized to treatment with paclitaxel eluting stent will receive the Zilver® PTX® stent.Primary stenting should be performed covering the full lesion. Post-dilatation is at the investigator's discretion.

Group Type: EXPERIMENTAL

Paclitaxel Eluting Stent

Intervention Type: DEVICE

Paclitaxel Eluting Balloon

For patients randomized to treatment with drug eluting balloon (DEB), angioplasty (ballooning) should be performed covering the full lesion.

Group Type: ACTIVE_COMPARATOR

Paclitaxel Eluting Balloon

Intervention Type: DEVICE

Interventions

Paclitaxel Eluting Stent

Intervention Type: DEVICE

Paclitaxel Eluting Balloon

Intervention Type: DEVICE

Other Intervention Names

Zilver PTX stent

Eligibility Criteria

Inclusion Criteria

• Subject age ≥ 18
• Subject has been informed of the nature of the study, agrees to participate, and has signed a Medical Ethics Committee approved consent form.
• Subject understands the duration of the study, agrees to attend follow-up visits, and agrees to complete the required testing.
• Rutherford category 2-5.
• Subject has a de novo or restenotic lesion with ≥ 70% stenosis documented angiographically and no prior stent in the target lesion.
• Target lesion is at least 1cm below the origin of the profunda femoris and does not exceed the medial femoral epicondyle.
• A single target lesion (stenotic areas separated by more than 3 cm with ≤ 30% stenosis might, at the decision of the investigator, be considered as 2 lesions).
• Reference vessel diameter (RVD) ≥ 4 mm and ≤ 6.5 mm by visual assessment.
• Patency of at least one (1) infrapopliteal artery to the ankle (< 50% diameter stenosis) in continuity with the native femoropopliteal artery.
• A guidewire has successfully traversed the target treatment segment.

Exclusion Criteria

• Inability to obtain informed consent.
• Life expectancy < 12 months.
• Pregnancy, suspected pregnancy, or breastfeeding during study period (patients of childbearing potential must have negative serum pregnancy test 7 days prior to treatment).
• Presence of one or more of the following co-morbid factors: hemodialysis dependence, renal insufficiency with a serum creatinine ≥ 2.5 mg/dl, cerebrovascular accident (CVA) within 1 month of procedure or any CVA resulting in unresolved walking impairment, and/or myocardial infarction (MI) within 1 month of procedure.
• Any evidence of hemodynamic instability prior to procedure/randomization.
• Coagulopathy or clotting disorders.
• Present or suspected systemic infection or osteomyelitis affecting target limb.
• Contraindication to contrast media or any study-required medication (antiplatelets, anticoagulants, thrombolytics, etc).
• Hypersensitivity to nitinol and/or paclitaxel.
• Enrollment into another study.
• Intervention of the target lesion less than 90 days prior of the study procedure.

• Untreated external iliac artery inflow lesion (study allows for successful treatment prior to study treatment procedures).
• Total occlusion uncrossable by a conventional guidewire.
• Acute occlusive intraluminal thrombosis of the proposed lesion site.
• Evidence of an aneurysm at the target lesion site.
• Perforation in the target vessel as evidenced by the extravasation of contrast.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

William Cook Europe

INDUSTRY

Sponsor Role: collaborator

Provascular GmbH

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dierk Scheinert, MD

Role: PRINCIPAL_INVESTIGATOR

Park Hospital Leipzig

Locations

Imelda Hospital

Bonheiden, , Belgium

AZ Sint-Blasius Department of Vascular Surgery

Dendermonde, , Belgium

Universitäts Herzzentrum Freiburg Bad Krozingen Abteilung Angiologie

Bad Krozingen, , Germany

Angiologikum Hamburg Centre for Interventional Vascular Medicine

Hamburg, , Germany

Park-Krankenhaus Leipzig

Leipzig, , Germany

Countries

Belgium; Germany

References

Bausback Y, Wittig T, Schmidt A, Zeller T, Bosiers M, Peeters P, Brucks S, Lottes AE, Scheinert D, Steiner S. Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease. J Am Coll Cardiol. 2019 Feb 19;73(6):667-679. doi: 10.1016/j.jacc.2018.11.039.

Reference Type: DERIVED

PMID: 30765033 (View on PubMed)

Other Identifiers

U1111-1136-8610

Identifier Type: OTHER

Identifier Source: secondary_id

Prov 01-2012

Identifier Type: -

Identifier Source: org_study_id